CLAIMS

1. Isolated solid form of anamorelin monohydrochloride, wherein said anamorelin monohydrochloride has a chloride:anamorelin molar ratio of from 0.9 to 0.99, comprising a residual content of organic solvent being less than 5000 ppm.

2. The isolated form of anamorelin monohydrochloride according to claim 1, wherein the residual content of organic solvent is less than 3000 ppm.

3. The isolated form of anamorelin monohydrochloride according to claim 1, wherein the residual content of organic solvent is less than 1000 ppm.

4. A pharmaceutical composition comprising:

   a) a therapeutically effective amount of the anamorelin monohydrochloride of claims 1,2,or 3; and

   b) one or more pharmaceutically acceptable excipients.

5. A method of making a pharmaceutical dosage form comprising:

   a) combining a therapeutically effective amount of the anamorelin monohydrochloride of claims 1,2 or 3 with one or more pharmaceutically acceptable excipients to form a mixture; and

   b) processing said mixture into a finished dosage form.